Genincode (GENI.L) Stock Price

Genincode Price

LSE·CLOSED
0.01GBP+0.00 (+0.00 %)
Market closed

Revenue has compounded at 29.5% per year over the past 4 years to 2.70 M GBP. Genincode's net margin stands at -164.2%, down from -121.9% several years earlier. Analysts set a median price target of 11.73 GBP, implying 146,525.0% above the current price. Of 5 analysts, 4 rate the stock a buy — an overall Buy consensus. The stock trades about 3% above its 52-week low.

Genincode stock price

Volume
Details

Stock Price

ⓘ

How to Read This Chart

This chart tracks the historical stock price of Genincode over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Genincode stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Genincode's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

Genincode Stock Price History
DateGenincode Price
7/31/20260.01 GBP
7/30/20260.01 GBP
7/29/20260.01 GBP
7/28/20260.01 GBP
7/27/20260.01 GBP
7/24/20260.01 GBP
7/23/20260.01 GBP
7/22/20260.01 GBP
7/21/20260.01 GBP
7/20/20260.01 GBP
7/17/20260.01 GBP
7/16/20260.01 GBP
7/15/20260.01 GBP
7/14/20260.01 GBP
7/13/20260.01 GBP
7/10/20260.01 GBP
7/9/20260.01 GBP
7/8/20260.01 GBP
7/7/20260.01 GBP
7/6/20260.01 GBP
7/3/20260.01 GBP
7/2/20260.01 GBP
7/1/20260.01 GBP
6/30/20260.01 GBP
6/29/20260.01 GBP
6/26/20260.01 GBP
6/25/20260.01 GBP
6/24/20260.01 GBP
6/23/20260.01 GBP
6/22/20260.01 GBP
6/19/20260.01 GBP
6/18/20260.01 GBP
6/17/20260.01 GBP
6/16/20260.01 GBP
6/15/20260.01 GBP
6/12/20260.01 GBP
6/11/20260.01 GBP
6/10/20260.01 GBP
6/9/20260.01 GBP
6/8/20260.01 GBP
6/5/20260.01 GBP
6/4/20260.01 GBP
6/3/20260.01 GBP
6/2/20260.01 GBP
6/1/20260.01 GBP
5/29/20260.01 GBP
5/28/20260.01 GBP
5/27/20260.01 GBP
5/26/20260.01 GBP
5/22/20260.01 GBP
5/21/20260.01 GBP
5/20/20260.01 GBP
5/19/20260.01 GBP
5/18/20260.01 GBP
5/15/20260.01 GBP
5/14/20260.01 GBP
5/13/20260.01 GBP
5/12/20260.01 GBP
5/11/20260.01 GBP
5/8/20260.01 GBP
5/7/20260.01 GBP
5/6/20260.01 GBP
5/5/20260.01 GBP
5/1/20260.01 GBP
4/30/20260.01 GBP
4/29/20260.01 GBP
4/28/20260.01 GBP
4/27/20260.01 GBP
4/24/20260.01 GBP
4/23/20260.01 GBP
4/22/20260.01 GBP
4/21/20260.01 GBP
4/20/20260.01 GBP
4/17/20260.01 GBP
4/16/20260.01 GBP
4/15/20260.01 GBP
4/14/20260.01 GBP
4/13/20260.01 GBP
4/10/20260.01 GBP
4/9/20260.01 GBP
4/8/20260.01 GBP
4/7/20260.01 GBP
4/2/20260.01 GBP
4/1/20260.01 GBP
3/31/20260.01 GBP
3/30/20260.01 GBP
3/27/20260.01 GBP
3/26/20260.01 GBP
3/25/20260.01 GBP
3/24/20260.01 GBP
3/23/20260.01 GBP
3/20/20260.01 GBP
3/19/20260.01 GBP
3/18/20260.01 GBP
3/17/20260.01 GBP
3/16/20260.01 GBP
3/13/20260.01 GBP
3/12/20260.01 GBP
3/11/20260.01 GBP
3/10/20260.01 GBP
3/9/20260.01 GBP
3/6/20260.01 GBP
3/5/20260.01 GBP
3/4/20260.01 GBP
3/3/20260.01 GBP
3/2/20260.01 GBP
2/27/20260.01 GBP
2/26/20260.01 GBP
2/25/20260.01 GBP
2/24/20260.01 GBP
2/23/20260.01 GBP
2/20/20260.01 GBP
2/19/20260.01 GBP
2/18/20260.01 GBP
2/17/20260.01 GBP
2/16/20260.01 GBP
2/13/20260.01 GBP
2/12/20260.01 GBP
2/11/20260.01 GBP
2/10/20260.01 GBP
2/9/20260.01 GBP
2/6/20260.01 GBP
2/5/20260.01 GBP
2/4/20260.01 GBP
2/3/20260.01 GBP
2/2/20260.01 GBP
1/30/20260.01 GBP
1/29/20260.01 GBP
1/28/20260.01 GBP
1/27/20260.01 GBP
1/26/20260.01 GBP
1/23/20260.01 GBP
1/22/20260.01 GBP
1/21/20260.01 GBP
1/20/20260.01 GBP
1/19/20260.01 GBP
1/16/20260.01 GBP
1/15/20260.01 GBP
1/14/20260.01 GBP
1/13/20260.01 GBP
1/12/20260.01 GBP
1/9/20260.01 GBP
1/8/20260.01 GBP
1/7/20260.01 GBP
1/6/20260.01 GBP
1/5/20260.02 GBP
1/2/20260.01 GBP
12/31/20250.01 GBP
12/30/20250.02 GBP
12/29/20250.01 GBP
12/24/20250.01 GBP
12/23/20250.01 GBP
12/22/20250.02 GBP
12/19/20250.02 GBP
12/18/20250.02 GBP
12/17/20250.02 GBP
12/16/20250.02 GBP
12/15/20250.02 GBP
12/12/20250.02 GBP
12/11/20250.02 GBP
12/10/20250.02 GBP
12/9/20250.02 GBP
12/8/20250.02 GBP
12/5/20250.02 GBP
12/4/20250.02 GBP
12/3/20250.02 GBP
12/2/20250.01 GBP
12/1/20250.01 GBP
11/28/20250.01 GBP
11/27/20250.01 GBP
11/26/20250.01 GBP
11/25/20250.01 GBP
11/24/20250.01 GBP
11/21/20250.01 GBP
11/20/20250.01 GBP
11/19/20250.01 GBP
11/18/20250.01 GBP
11/17/20250.01 GBP
11/14/20250.01 GBP
11/13/20250.02 GBP
11/12/20250.02 GBP
11/11/20250.02 GBP
11/10/20250.02 GBP
11/7/20250.02 GBP
11/6/20250.02 GBP
11/5/20250.02 GBP
11/4/20250.02 GBP
11/3/20250.02 GBP
10/31/20250.02 GBP
10/30/20250.02 GBP
10/29/20250.02 GBP
10/28/20250.02 GBP
10/27/20250.02 GBP
10/24/20250.02 GBP
10/23/20250.02 GBP
10/22/20250.02 GBP
10/21/20250.02 GBP
10/20/20250.02 GBP
10/17/20250.02 GBP
10/16/20250.02 GBP
10/15/20250.02 GBP
10/14/20250.02 GBP
10/13/20250.02 GBP
10/10/20250.02 GBP
10/9/20250.02 GBP
10/8/20250.02 GBP
10/7/20250.02 GBP
10/6/20250.02 GBP
10/3/20250.02 GBP
10/2/20250.02 GBP
10/1/20250.02 GBP
9/30/20250.02 GBP
9/29/20250.03 GBP
9/26/20250.03 GBP
9/25/20250.03 GBP
9/24/20250.03 GBP
9/23/20250.03 GBP
9/22/20250.03 GBP
9/19/20250.02 GBP
9/18/20250.02 GBP
9/17/20250.03 GBP
9/16/20250.02 GBP
9/15/20250.01 GBP
9/12/20250.01 GBP
9/11/20250.01 GBP
9/10/20250.01 GBP
9/9/20250.01 GBP
9/8/20250.01 GBP
9/5/20250.01 GBP
9/4/20250.01 GBP
9/3/20250.01 GBP
9/2/20250.01 GBP
9/1/20250.01 GBP
8/29/20250.01 GBP
8/28/20250.01 GBP
8/27/20250.01 GBP
8/26/20250.01 GBP
8/22/20250.01 GBP
8/21/20250.01 GBP
8/20/20250.01 GBP
8/19/20250.01 GBP
8/18/20250.01 GBP
8/15/20250.01 GBP
8/14/20250.01 GBP
8/13/20250.01 GBP
8/12/20250.01 GBP
8/11/20250.01 GBP
8/8/20250.01 GBP
8/7/20250.01 GBP
8/6/20250.01 GBP
8/5/20250.01 GBP
8/4/20250.01 GBP
Access this data via the Eulerpool API
Get Free API Key

Genincode Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2022
1.43 M GBP
-5.90 M GBP
-5.56 M GBP
Jan 1, 2023
2.16 M GBP
-7.15 M GBP
-7.02 M GBP
Jan 1, 2024
2.70 M GBP
-4.99 M GBP
-4.43 M GBP
Jan 1, 2025 (e)
3.13 M GBP
-4.65 M GBP
-5.51 M GBP
Jan 1, 2026 (e)
4.75 M GBP
0.00 GBP
0.00 GBP
Jan 1, 2027 (e)
50.56 M GBP
0.00 GBP
0.00 GBP
Jan 1, 2028 (e)
70.25 M GBP
0.00 GBP
0.00 GBP
Jan 1, 2029 (e)
104.35 M GBP
0.00 GBP
0.00 GBP

Genincode Income Statement, Balance Sheet, Cash Flow Statement

Last updated Aug 4, 2026, 7:24 AM
 
REVENUEM GBP
REVENUE GROWTH%
GROSS MARGIN%
GROSS INCOMEM GBP
EBITM GBP
EBIT MARGIN%
NET INCOMEM GBP
NET INCOME GROWTH%
SHARESM
202020212022202320242025e2026e2027e2028e2029e
–1.001.002.002.003.004.0050.0070.00104.00
–––100.00–50.0033.331,150.0040.0048.57
–100.00100.0050.0050.0050.0050.0050.0050.0050.00
1.001.001.001.001.001.502.0025.0035.0052.00
-1.00-3.00-5.00-7.00-4.00-4.00––––
–-300.00-500.00-350.00-200.00-133.33––––
-1.00-4.00-5.00-7.00-4.00-5.00––––
–300.0025.0040.00-42.8625.00––––
95.8295.8295.8295.82175.02175.02175.02175.02175.02175.02
Details

Income Statement Key Figures

ⓘ

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales Genincode generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Genincode retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Genincode's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares Genincode has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Genincode's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

Genincode stock margins

The Genincode margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Genincode. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Genincode.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2020
54.17 %
-109.38 %
-121.88 %
Jan 1, 2021
51.30 %
-307.83 %
-360.00 %
Jan 1, 2022
44.20 %
-412.52 %
-388.74 %
Jan 1, 2023
47.31 %
-331.06 %
-324.81 %
Jan 1, 2024
52.80 %
-184.56 %
-164.16 %
Jan 1, 2025 (e)
52.80 %
-148.39 %
-175.83 %
Jan 1, 2026 (e)
52.80 %
0.00 %
0.00 %
Jan 1, 2027 (e)
52.80 %
0.00 %
0.00 %

Genincode Stock Revenue, EBIT, Earnings per Share

The Genincode earnings per share therefore indicates how much revenue Genincode has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
EBIT per share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2020
0.01 GBP
-0.01 GBP
-0.01 GBP
Jan 1, 2021
0.01 GBP
-0.04 GBP
-0.04 GBP
Jan 1, 2022
0.01 GBP
-0.06 GBP
-0.06 GBP
Jan 1, 2023
0.02 GBP
-0.07 GBP
-0.07 GBP
Jan 1, 2024
0.02 GBP
-0.03 GBP
-0.03 GBP
Jan 1, 2025 (e)
0.01 GBP
-0.03 GBP
-0.02 GBP
Jan 1, 2026 (e)
0.02 GBP
0.00 GBP
0.00 GBP
Jan 1, 2027 (e)
0.18 GBP
0.00 GBP
0.00 GBP

Genincode business model & stock analysis

Genincode Eulerpool Fair Value

Details

Fair Value Estimate

ⓘ

What Is Fair Value?

Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.

Earnings-Based Fair Value

Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.

Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021

Revenue-Based Fair Value

Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"

Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021

Dividend-Based Fair Value

Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.

Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021

How to Use This Chart

When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.

Genincode historical P/E ratio, EBIT multiple, and P/S ratio

Genincode annual returns

Details

Annual Return

ⓘ

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

Genincode shares outstanding

The number of shares of Genincode was 175.02 M in 2025. This indicates how many shares Genincode is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2020
95.82 M Stocks
Jan 1, 2021
95.82 M Stocks
Jan 1, 2022
95.82 M Stocks
Jan 1, 2023
95.82 M Stocks
Jan 1, 2024
175.02 M Stocks
Jan 1, 2025 (e)
175.02 M Stocks
Jan 1, 2026 (e)
175.02 M Stocks
Jan 1, 2027 (e)
175.02 M Stocks

Current Genincode forecasts and price targets in August 2026

Analyst Price Targets 2026
Δ MOM Price Target
0.00 %
Buy
80.00 % (4)
Hold
20.00 % (1)
Sell
0.00 % (0)
12M Price Target
0.12
Last Price
0.01
Currency
GBP
12M Return Potential
1,366.25 %
LTM Return
0 %

Genincode Earnings Estimates & Surprises

DateEPS estimateEPS ActualRevenue EstimatePrice reactionQuarterly report
6/4/2024-0.04GBP-1.52 MGBP-2023 Q4

Genincode shareholder structure

% Name
18.43185%
Octopus Investments Limited
Octopus Investments Limited
13.03274%
Maven Capital Partners UK LLP
Maven Capital Partners UK LLP
12.40783%
Santi 1990 SL
Santi 1990 SL
5.13721%
Puig (Jordi)
Puig (Jordi)
5.13721%
Gilberte (Jordi Puig)
Gilberte (Jordi Puig)
4.91636%
Dowgate Capital Limited (Asset Management)
Dowgate Capital Limited (Asset Management)

Genincode Executives and Management Board

7 members · 0 % women

MW

Mr. Matthew Walls

Chief Executive Officer, Executive Director · since 2018

297,046.00 GBP

Management

PF

Mr. Paul Foulger

Chief Financial Officer, Executive Director, Company Secretary · since 2021

181,089.00 GBP
JG

Mr. Jordi Gilberte

Chief Operating Officer, Executive Director · since 2018

170,942.00 GBP

Board of Directors

WR

Mr. William Rhodes

Independent Non-Executive Chairman of the Board

58,793.00 GBP
PG

Prof. Huon Gray

Independent Non-Executive Director

38,332.00 GBP
FF

Mr. Felix Frueh

Independent Non-Executive Director

38,218.00 GBP
SO

Mr. Sergio Olivero

Independent Non-Executive Director

–

Frequently asked questions about Genincode

Analysts currently set an average price target of 11.73 GBP for the Genincode stock (median: 11.73 GBP), implying +1,366.2 % versus the latest price. The consensus is based on 5 analyst ratings.

Genincode Analyst Price Targets 2026

5 analysts currently rate the Genincode stock: 4 recommend buying, 1 holding and 0 selling.

Genincode Analyst Price Targets 2026

Converted at the current exchange rate, the Genincode share trades at 0.01 EUR (0.01 GBP).

The Genincode share (GENI.L) is listed on 3 stock exchanges, including: Frankfurt (9PL.F), London (GENI.L), London (GENI.L).

No history available for Genincode.

The expected revenue of Genincode is 4.75 M GBP. This figure is based on current financial data and reflects the company's business performance.

The profit cannot currently be calculated for Genincode.

The P/E ratio cannot be calculated for Genincode at the moment.

The price-to-sales ratio (P/S) of Genincode is currently 0.29. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Genincode stock.

The Eulerpool Quality Score for Genincode is 3/10.

The ISIN of Genincode is GB00BL97B504. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of Genincode is A3C31Y. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of Genincode is GENI.L. The ticker symbol is used to trade Genincode shares on the stock exchange.

Genincode paid dividends every year for the past 0 years.

Genincode is assigned to the 'Health' sector.

The dividends of Genincode are distributed in GBP.

All fundamentals and in-depth analysis of Genincode

Our stock analysis for Genincode stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Genincode. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.

Genincode Stock
Genincode Revenue→
Genincode Stock
Genincode Net Income→
Genincode Stock
Genincode P/E→
Genincode Stock
Genincode P/S→
Genincode Stock
Genincode EBIT→
Genincode Stock
Genincode Dividend→
Genincode Stock
Genincode Directors Dealings→
Genincode Stock
Genincode Stocks→
Genincode Stock
Genincode Market capitalization→
Genincode Stock
Genincode Debt→
Genincode Stock
Genincode Liabilities→
Genincode Stock
Genincode Equity→
Genincode Stock
Genincode AAQS→
Genincode Stock
Genincode Employees→
Genincode Stock
Genincode ROE→
Genincode Stock
Genincode ROA→
Genincode Stock
Genincode ROCE→
Genincode Stock
Genincode News→
Genincode Stock
Genincode Analyst Price Targets→

Health Stocks

GeninusGenflow BiosciencesGenmab ASGenfitGenMont BiotechGenexineGennex LaboratoriesGenex PharmaceuticalGenocea BiosciencesGenetics Generation AdvancementGenolutionGenetic TechnologiesAll Stocks A–Z →